![Novel multiomic imaging enhances spatial high-plex protein imaging with the ability to elucidate metabolic processes in the same tissue section. In addition to mapping tens to over one hundred targeted proteins with high-plex peptide tags, MALDI HiPLEX-IHC can track signalling pathways such as glycosylation, observe lipid spatial profiles for tumour microenvironment segmentation, or simultaneously observe how drugs affect both protein and metabolic states.](/sites/default/files/styles/product_photo/public/np/maldi-hiplex-ihc-w.jpg?itok=7LdDidEV)
Bruker has announced new developments for spatial multiomics of tissue and tumour microenvironments (TME). Following Bruker’s strategic partnership with AmberGen, enhancements have been introduced for MALDI HiPLEX-IHC mass spectrometry imaging. MALDI HiPLEX-IHC represents a breakthrough in multiomics imaging by combining targeted protein expression spatial profiling with unbiased small molecule MALDI imaging to co-localise proteins and small molecules such as glycans, lipids, metabolites or xenobiotics. Using AmberGen’s Miralys™ antibody-based photocleavable peptide mass tags, highly multiplexed IHC staining and photocleavage of peptide markers fit seamlessly into Bruker’s IntelliSlide®-based automated workflows for MALDI imaging.